TG Therapeutics, Inc. (0VGI.L)
USD 31.97
(-5.69%)
USD 31.97
(-5.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 20.63 Million USD | 110.7% |
| 2022 | -192.83 Million USD | 44.07% |
| 2021 | -344.77 Million USD | -26.02% |
| 2020 | -273.59 Million USD | -61.84% |
| 2019 | -169.05 Million USD | 3.06% |
| 2018 | -174.4 Million USD | -46.91% |
| 2017 | -118.71 Million USD | -50.33% |
| 2016 | -78.96 Million USD | -24.99% |
| 2015 | -63.18 Million USD | -13.39% |
| 2014 | -55.72 Million USD | -142.62% |
| 2013 | -22.96 Million USD | 14.61% |
| 2012 | -26.89 Million USD | -2949.42% |
| 2011 | -881.97 Thousand USD | 56.27% |
| 2010 | -2.01 Million USD | -13.84% |
| 2009 | -1.77 Million USD | 59.85% |
| 2008 | -4.41 Million USD | 63.66% |
| 2007 | -12.14 Million USD | -21.44% |
| 2006 | -10 Million USD | 48.34% |
| 2005 | -19.35 Million USD | -215.12% |
| 2004 | -6.14 Million USD | -29.1% |
| 2003 | -4.75 Million USD | -206.41% |
| 2002 | -1.55 Million USD | 50.02% |
| 2001 | -3.1 Million USD | 1.74% |
| 2000 | -3.16 Million USD | -17.13% |
| 1999 | -2.7 Million USD | 0.0% |
| 1998 | -2.7 Million USD | 49.06% |
| 1997 | -5.3 Million USD | -39.47% |
| 1996 | -3.8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.27 Million USD | 25.75% |
| 2024 Q2 | 8.81 Million USD | 195.1% |
| 2024 Q3 | 12.43 Million USD | 41.04% |
| 2023 Q2 | -44.67 Million USD | -20.77% |
| 2023 Q4 | -12.48 Million USD | -110.88% |
| 2023 Q1 | -36.99 Million USD | 28.95% |
| 2023 FY | 20.63 Million USD | 110.7% |
| 2023 Q3 | 114.78 Million USD | 356.94% |
| 2022 Q3 | -34.96 Million USD | 10.22% |
| 2022 Q4 | -52.06 Million USD | -48.91% |
| 2022 Q2 | -38.94 Million USD | 41.77% |
| 2022 FY | -192.83 Million USD | 44.07% |
| 2022 Q1 | -66.87 Million USD | 28.05% |
| 2021 Q1 | -89.2 Million USD | -2.79% |
| 2021 FY | -344.77 Million USD | -26.02% |
| 2021 Q2 | -77.49 Million USD | 13.13% |
| 2021 Q3 | -85.12 Million USD | -9.85% |
| 2021 Q4 | -92.94 Million USD | -9.18% |
| 2020 Q4 | -86.78 Million USD | -1.24% |
| 2020 Q3 | -85.72 Million USD | -68.59% |
| 2020 Q1 | -50.24 Million USD | -32.36% |
| 2020 FY | -273.59 Million USD | -61.84% |
| 2020 Q2 | -50.84 Million USD | -1.19% |
| 2019 FY | -169.05 Million USD | 3.06% |
| 2019 Q4 | -37.96 Million USD | 37.63% |
| 2019 Q1 | -34.68 Million USD | 35.94% |
| 2019 Q2 | -35.54 Million USD | -2.46% |
| 2019 Q3 | -60.86 Million USD | -71.23% |
| 2018 Q3 | -34.32 Million USD | 22.59% |
| 2018 Q4 | -54.15 Million USD | -57.74% |
| 2018 FY | -174.4 Million USD | -46.91% |
| 2018 Q1 | -41.57 Million USD | -33.97% |
| 2018 Q2 | -44.34 Million USD | -6.66% |
| 2017 Q3 | -31.58 Million USD | -11.12% |
| 2017 FY | -118.71 Million USD | -50.33% |
| 2017 Q4 | -31.03 Million USD | 1.74% |
| 2017 Q1 | -27.66 Million USD | -15.14% |
| 2017 Q2 | -28.42 Million USD | -2.74% |
| 2016 FY | -78.96 Million USD | -24.99% |
| 2016 Q1 | -13.99 Million USD | 20.68% |
| 2016 Q2 | -16.02 Million USD | -14.52% |
| 2016 Q3 | -24.92 Million USD | -55.56% |
| 2016 Q4 | -24.02 Million USD | 3.6% |
| 2015 Q4 | -17.64 Million USD | -27.59% |
| 2015 Q1 | -14.6 Million USD | 22.0% |
| 2015 Q2 | -17.11 Million USD | -17.18% |
| 2015 Q3 | -13.82 Million USD | 19.2% |
| 2015 FY | -63.18 Million USD | -13.39% |
| 2014 Q4 | -18.72 Million USD | -7.35% |
| 2014 FY | -55.72 Million USD | -142.62% |
| 2014 Q3 | -17.43 Million USD | -45.87% |
| 2014 Q2 | -11.95 Million USD | -57.2% |
| 2014 Q1 | -7.6 Million USD | 4.65% |
| 2013 Q2 | -6.62 Million USD | -78.48% |
| 2013 Q1 | -3.71 Million USD | -0.64% |
| 2013 FY | -22.96 Million USD | 14.61% |
| 2013 Q4 | -7.97 Million USD | -71.62% |
| 2013 Q3 | -4.64 Million USD | 29.89% |
| 2012 Q3 | -2.71 Million USD | 12.58% |
| 2012 Q4 | -3.69 Million USD | -35.97% |
| 2012 FY | -26.89 Million USD | -2949.42% |
| 2012 Q1 | -17.38 Million USD | -6566.32% |
| 2012 Q2 | -3.1 Million USD | 82.14% |
| 2011 Q2 | -322.9 Thousand USD | 42.96% |
| 2011 Q3 | -261.84 Thousand USD | 18.91% |
| 2011 FY | -881.97 Thousand USD | 56.27% |
| 2011 Q4 | 268.86 Thousand USD | 202.68% |
| 2011 Q1 | -566.08 Thousand USD | -26.76% |
| 2010 Q1 | -529.44 Thousand USD | -55.12% |
| 2010 Q2 | -525.09 Thousand USD | 0.82% |
| 2010 Q3 | -515.63 Thousand USD | 1.8% |
| 2010 FY | -2.01 Million USD | -13.84% |
| 2010 Q4 | -446.56 Thousand USD | 13.39% |
| 2009 Q2 | -477.26 Thousand USD | 14.37% |
| 2009 Q3 | -395.64 Thousand USD | 17.1% |
| 2009 FY | -1.77 Million USD | 59.85% |
| 2009 Q4 | -341.32 Thousand USD | 13.73% |
| 2009 Q1 | -557.33 Thousand USD | -1166.61% |
| 2008 Q3 | -1.38 Million USD | 5.71% |
| 2008 Q4 | 52.25 Thousand USD | 103.78% |
| 2008 FY | -4.41 Million USD | 63.66% |
| 2008 Q1 | -1.61 Million USD | 15.88% |
| 2008 Q2 | -1.46 Million USD | 9.1% |
| 2007 Q1 | -2.59 Million USD | 18.43% |
| 2007 Q4 | -1.91 Million USD | 29.12% |
| 2007 Q3 | -2.7 Million USD | 45.02% |
| 2007 Q2 | -4.92 Million USD | -89.81% |
| 2007 FY | -12.14 Million USD | -21.44% |
| 2006 Q1 | -2.91 Million USD | -10.39% |
| 2006 Q2 | -2.35 Million USD | 19.11% |
| 2006 Q4 | -3.18 Million USD | -61.81% |
| 2006 Q3 | -1.96 Million USD | 16.62% |
| 2006 FY | -10 Million USD | 48.34% |
| 2005 Q4 | -2.63 Million USD | -41.81% |
| 2005 Q2 | -13.39 Million USD | -819.4% |
| 2005 FY | -19.35 Million USD | -215.12% |
| 2005 Q1 | -1.45 Million USD | 18.67% |
| 2005 Q3 | -1.86 Million USD | 86.11% |
| 2004 Q3 | -2.24 Million USD | -127.19% |
| 2004 Q1 | -1.12 Million USD | 26.17% |
| 2004 Q4 | -1.79 Million USD | 20.06% |
| 2004 FY | -6.14 Million USD | -29.1% |
| 2004 Q2 | -986.71 Thousand USD | 12.1% |
| 2003 FY | -4.75 Million USD | -206.41% |
| 2003 Q1 | -422.22 Thousand USD | -15.23% |
| 2003 Q2 | -777.02 Thousand USD | -84.03% |
| 2003 Q3 | -2.03 Million USD | -162.38% |
| 2003 Q4 | -1.52 Million USD | 25.43% |
| 2002 Q1 | -629.59 Thousand USD | -12.79% |
| 2002 Q3 | -588.24 Thousand USD | -1977.74% |
| 2002 FY | -1.55 Million USD | 50.02% |
| 2002 Q4 | -366.4 Thousand USD | 37.71% |
| 2002 Q2 | 31.32 Thousand USD | 104.98% |
| 2001 Q4 | -558.19 Thousand USD | 20.77% |
| 2001 FY | -3.1 Million USD | 1.74% |
| 2001 Q1 | -251.33 Thousand USD | -110.85% |
| 2001 Q2 | -1.47 Million USD | -486.21% |
| 2001 Q3 | -704.51 Thousand USD | 52.18% |
| 2000 Q3 | -963.45 Thousand USD | 68.9% |
| 2000 Q1 | -1.41 Million USD | -136.41% |
| 2000 FY | -3.16 Million USD | -17.13% |
| 2000 Q2 | -3.09 Million USD | -118.4% |
| 2000 Q4 | 2.31 Million USD | 340.51% |
| 1999 FY | -2.7 Million USD | 0.0% |
| 1999 Q4 | -600 Thousand USD | -20.0% |
| 1999 Q3 | -500 Thousand USD | 16.67% |
| 1999 Q2 | -600 Thousand USD | 33.33% |
| 1999 Q1 | -900 Thousand USD | 0.0% |
| 1998 FY | -2.7 Million USD | 49.06% |
| 1998 Q2 | 800 Thousand USD | 161.54% |
| 1998 Q3 | -1.2 Million USD | -250.0% |
| 1998 Q4 | -900 Thousand USD | 25.0% |
| 1998 Q1 | -1.3 Million USD | 18.75% |
| 1997 Q3 | -1 Million USD | 41.18% |
| 1997 Q4 | -1.6 Million USD | -60.0% |
| 1997 FY | -5.3 Million USD | -39.47% |
| 1997 Q1 | -800 Thousand USD | 33.33% |
| 1997 Q2 | -1.7 Million USD | -112.5% |
| 1996 Q3 | -1.1 Million USD | -83.33% |
| 1996 Q4 | -1.2 Million USD | -9.09% |
| 1996 FY | -3.8 Million USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | -600 Thousand USD | -700.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 112.196% |
| Dynavax Technologies Corporation | -37.02 Million USD | 155.723% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 116.983% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 100.147% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 491.592% |
| Perrigo Company plc | 151.9 Million USD | 86.417% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 107.476% |
| Illumina, Inc. | -1.06 Billion USD | 101.93% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 99.699% |
| Nektar Therapeutics | -137.42 Million USD | 115.014% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 104.48% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 98.956% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 118.653% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 146.193% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 89.389% |
| Waters Corporation | 817.67 Million USD | 97.477% |
| Biogen Inc. | 1.29 Billion USD | 98.409% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 107.53% |
| Adicet Bio, Inc. | -152.03 Million USD | 113.571% |
| Evolus, Inc. | -49.23 Million USD | 141.909% |
| bluebird bio, Inc. | -244.26 Million USD | 108.447% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 121.193% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 113.263% |
| FibroGen, Inc. | -281.81 Million USD | 107.321% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 98.472% |
| Homology Medicines, Inc. | -48.25 Million USD | 142.758% |
| Geron Corporation | -193.94 Million USD | 110.639% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 107.312% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 145.772% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 128.074% |
| Myriad Genetics, Inc. | -123.7 Million USD | 116.68% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 99.49% |
| OPKO Health, Inc. | -157.02 Million USD | 113.14% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 120.464% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 104.004% |
| Zoetis Inc. | 3.06 Billion USD | 99.328% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 142.807% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 98.102% |
| Exelixis, Inc. | 170.88 Million USD | 87.926% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 99.521% |
| uniQure N.V. | -282.87 Million USD | 107.294% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 152.698% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 137.006% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 108.9% |
| Verastem, Inc. | -92.08 Million USD | 122.407% |
| Imunon, Inc. | -21.03 Million USD | 198.11% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 105.833% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 107.704% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 91.776% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 80.768% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 93.888% |
| Blueprint Medicines Corporation | -486.27 Million USD | 104.243% |
| Insmed Incorporated | -709.62 Million USD | 102.908% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 105.27% |
| Incyte Corporation | 620.52 Million USD | 96.675% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 102.84% |